Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Multiple Myeloma 3Lymphoma 3Recurrence 2Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, B-Cell, Marginal Zone 2Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Leukemia 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × marizomib × Clear all
NCT00629473 2017-11-22

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Celgene

Phase 1 Completed
86 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Celgene

Phase 1 Completed
22 enrolled
DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Celgene

Phase 1 Completed
38 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡